← All trials
NCT04504864
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Aug 31, 2022
- First posted
- Aug 7, 2020
- Last posted
- Aug 18, 2020
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xijing HospitalLead sponsor
- People's Liberation Army of ChinaStudy director
- Jiao Tong UniversityCollaborator
- Shaanxi Provincial People's HospitalCollaborator
- People's Liberation Army of ChinaCollaborator
- Central South UniversityCollaborator
- Baoji Central HospitalCollaborator
- Xianyang Central HospitalCollaborator
- Jiao Tong UniversityCollaborator
- Xi'an Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.